| Neumega Agreement Renewal |
 |
| Oncology Associates is pleased to announce its renewed agreement with Wyeth Pharmaceuticals for purchases of Neumega (oprelvekin). The agreement offers a floating 5% discount to all OA Members and is effective March 1, 2007 to February 29, 2008. |
 |
 |
|
| Temporary 3% Aloxi Discount for OA Members |
|
| MGI Pharma, INC. is pleased to offer the following temporary Aloxi discount to OA Members who are currently at the 12% Additional Discount contract pricing tier. |
|
| Click here to learn more (pdf) |
|
|
|
| Pharmion Agreement Extension |
|
| Oncology Associates' agreement with Pharmion for Vidaza (azacitidine for injectable suspension) and Innohep (tinzaparin sodium for injection) has been extended through August 31, 2008. |
|
| Click here to learn more (pdf) |
|
|
|
| Ortho Biotech Agreement Renewed |
|
| Oncology Associates is pleased to announce that our agreement for Procrit (Epoetin alfa) and DOXIL (doxorubicin HCl liposome injection) has been renewed with Ortho Biotech. The agreement runs from May 1, 2007 through April 30, 2010 and offers a 1% discount on purchases of Procrit and DOXIL. |
|
| Click here to learn more (pdf) |
|
|
|
| Updated Aloxi Agreement for OA Members: Additional Rebate and Discount Opportunities |
|
| The new contract period for Aloxi will run from October 1, 2006 to September 30, 2007. The contract terms (discount tiers and rebates) for the current contract period will remain the same as in the last contract period (October 1, 2005 – September 30, 2006). |
|
|
|
| Eloxatin Added to Sanofi Aventis Agreement |
|
| Effective January 1, 2007, Eloxatin (oxaliplatin injection) is available to OA Members as part of our agreement with Sanofi Aventis. The product is available in 50 mg and 100 mg vials. The agreement will continue until December 31, 2008. |
|
|
|
| Ondansetron Now Available from Bedford Laboratories |
|
| Ondansetron Injection USP (AP rated to Zofran®) is now available to OA Members as part of our agreement with Bedford Laboratories. The product is available in the following presentations: 4 mg/2 mL SD vial and 40 mg/20 mL MD vial. Ondansetron Injection USP is Latex free and preservative free (SD vial only). The product is available through FloridaInfusion. Please contact your representative to place an order. |
|
|
|
| OA Partners with CSI Labs- Revenue Opportunity for OA Members |
|
| Oncology Associates is pleased to announce a new partnership with CSI Labs, a lab specializing in Flow Cytometry, Hematopathology Consultations, Cytogenetics and FISH. |
|
| Click here to learn more (pdf) |
|
|
|
| Ethyol Contract Extension |
|
| Oncology Associates’ agreement with MedImmune Oncology has been extended, effective January 1, 2006. The agreement will run until June 30, 2006 and provides discounted pricing for the product Ethyol. |
|
| Click here to learn more (pdf) |
|
|
|
| New Contract Amendment for Aloxi |
|
| MGI PHARMA offers a new contract amendment to OA’s product agreement for Aloxi, which runs until December 1, 2006. The agreement offers a new contract price, as well as individual unit market share additional discounts and individual unit market share rebates. |
|
| Click here to learn more (pdf) |
|
|
|
| SuperGen, Inc. Awards OA Product Agreement for Nipent |
|
| The agreement for Nipent runs from January 1, 2006 to December 31, 2006. |
|
| Click here to learn more (pdf) |
|
|
|
| New Kytril and XELODA Agreement for 2006 |
|
| OA is pleased to announce the continuation of our Roche agreement for Kytril and XELODA. The terms of this contract extension will continue through December 31, 2007. |
|
| Click here to learn more (pdf) |
|
|
|
| GlaxoSmithKline Contract Extension |
|
| OA is pleased to announce a contract extension for the following GlaxoSmithKline products: Arixtra, Hycamtin and Zofran. |
|
| Click here to learn more (pdf) |
|
|
|
| New Taxotere and Anzemet Agreement |
|
| Effective January 1, 2006 through December 31, 2006. |
|
| Click here to learn more (pdf) |
|
|
|
| Novartis Extends Agreement for Zometa |
|
| Effective January 1, 2006 to June 30, 2006- OA Members will receive a significant discount of 4%. The product is available in 4 mg/5 mL vials. |
|
|
|
| OA Partners with Microsys to Provide Practice Management Software |
|
| Oncology Associates is excited to partner with MICROSYS, the providers of MicroMD, a comprehensive Practice Management System. |
|
| Click here to learn more (pdf) |
|
|
|
| Amendment to GSK Agreement |
|
| Effective October 1, 2005 OA offers an additional performance rebate on Zofran Premixed Bag based on quarterly purchasing volume. OA members also have the opportunity to qualify for a performance rebate on Arixtra Injection. |
|
| Click here to learn more (pdf) |
|
|
|
| New Baxter Agreement for WinRho SDF |
|
| Effective April 19, 2005, WinRho® SDF [Rho(D) Immune Globlulin Intravenous (Human)] is available as part of the new OA agreement with Baxter. The product is available in 120 mcg, 300 mcg and 1000 mcg vials. This agreement will run until March 31, 2006. |
|
| Click here to learn more (pdf) |
|
|
|
| New Ortho Biotech Agreement for DOXIL and PROCRIT |
|
| Effective July 1, 2005 Oncology Associates offers a new agreement for Doxil (doxorubicin HCl liposome injection) and PROCRIT (Epoetin alfa). The new agreement will run until June 30, 2007. DOXIL is offered in 20 mg and 50 mg vials and is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. |
|
| Click here to learn more (pdf) |
|
|
|
| Octreotide Acetate Injection added to Bedford Agreement |
|
| Effective April 4, 2005, Octreotide Acetate Injection has been added to the Bedford Laboratories agreement. Bedford Laboratories will provide Octreotide Acetate Injection in five presentations: 50 mcg/1mL, 100 mcg/1mL, 500 mcg/1mL, 200mcg/mL, 5mL, and 1mg/mL 5mL octreotide (as acetate). |
|
| Click here to learn more (pdf) |
|
|
|
| Greater Upfront Discount on Zofran |
|
| Effective April 1, 2005, earn a greater upfront discount on Zofran 32ml bags. The market share and performance rebate tiers on the Zofran 32ml Bags is reduced to a single tier (i.e. a clinic with a 60% or greater market share will earn a 10% rebate on the 32ml bags). |
|
| Click here to learn more (pdf) |
|
|
|
| Arixtra Added to GlaxoSmithKline Agreement with Performance Rebate |
|
| Upfront discount of 10% with a performance rebate up to 15% available. |
|
|
|
| Novartis Extends Agreement for Zometa |
|
| Effective July 1, 2005, the OA agreement for Zometa has been extended through December 31, 2005. Zometa is offered to all OA members in good standing at a significant discount of 4%. The product is available in 4mg/5mL vials. |
|
| Click here to learn more (pdf) |
|
|
|
| New Aloxi Discount Program |
|
| Back-end rebates for Aloxi have been replaced with upfront pricing. OA Members will have the opportunity to earn a maximum of 12% discounted price on Aloxi. Please contact OA for details at 888-732-7352 |
|
|
|
| New sanofi aventis Agreement for Taxotere® |
|
| The current market share agreement for Taxotere® will be ending March 31, 2005. Beginning April 1, 2005, all eligible OA Members in good standing will receive an upfront 10% discount on Taxotere® purchases. This new agreement will not require OA Members to report market share via the website. |
|
| Click here to learn more (pdf) |
|
|
|
| New Zometa Agreement from Novartis |
|
| Oncology Associates is pleased to announce a new agreement for ZOMETA (zoledronic acid), effective January 1, 2005. Zometa is offered to all OA members in good standing at a significant discount of 4%. The product is available in 4 mg/5mL vials. |
|
| Click here to learn more (pdf) |
|
|
|
| Greater Upfront Discount on Zofran |
|
| Effective April 1, 2005, Earn a greater upfront discount on Zofran 32ml bags. The market share and performance rebate tiers on the Zofran 32ml Bags is reduced to a single tier. |
|
| Click here to learn more (pdf) |
|
|
|
| Arixtra Added to GlaxoSmithKline Agreement |
|
| Upfront discount of 10% with a performance rebate up to 15% available. Contact Oncology Associates at 888-732-7352 for more information about the GlaxoSmithKline agreement. |
|
|
|
| Novartis Agreement Highlights for Zometa |
|
|
Agreement effective January 1, 2005
Offered to all OA members in good standing
Significant 4% discount
Available in 4 mg/5 mL vials
|
|
|
|
| Wyeth Agreement Renewal for Neumega |
|
| Oncology Associates is pleased to renew the following agreement for Neumega, effective January 1, 2005 through December 31, 2005. The agreement provides valuable savings for the product Neumega in 5 mg vials and 5 mg vials in 7/box quantities. |
|
| Click here to learn more (pdf) |
|
|
|
| New GlaxoSmithKline Agreement |
|
| Oncology Associates' new agreement with GlaxoSmithKline will run from January 1,2005 to December 31, 2005. Products on contract include: Hycamtin, Navelbine and Zofran Injection. |
|
|
Lower price available on Zofran 32 mL bags
Lower price on branded Navelbine and discounted Hycamtin pricing
Reduced market share requirement in order to earn a 14% rebate on Zofran
32 mL bags (first quarter only) (25%-64.99% market share results in a 14% rebate)
|
|
| Click here to learn more (pdf) |
|
|
|
| OA Renews Agreement for Ethyol with MedImmune |
|
| Oncology Associates is pleased to announce that it has renewed its agreement for Ethyol with MedImmune Oncology, Inc. The new agreement will begin January 1, 2005. |
|
| Click here to learn more (pdf) |
|
|
|
| New Kytril and XELODA Agreement for 2005 |
|
| Oncology Associates is pleased to announce a new Kytril (granisetron hydrochloride) dosage form for pediatric cancer patients, a 0.1mg/1 mL single-use vial to the Roche agreement, effective November 15, 2004. Effective January 1, 2005, members will no longer receive tier-based Kytril pricing. All eligible members will receive the same low upfront Kytril pricing. Roche has also introduced a first-ever clinical contract for XELODA (capecitabine). |
|
| Click here to learn more (pdf) |
|
|
|
| New Agreement for ZOMETA® |
|
| Oncology Associates is pleased to announce ZOMETA® (zoledronic acid) has been added to the Novartis agreement, effective October 1, 2004. The agreement will run until December 31, 2004 and is offered to all OA members in good standing at a significant discount of 5%. |
|
| Click here to learn more (pdf) |
|
|
|
| Sandostatin LAR® Rebates Released |
|
| As part of the OA product agreement for Sandostatin LAR®, we are pleased to announce the release of April and May 2004 rebate checks. Eligible members should have already received these checks, as they were issued on August 23, 2004 (April) and September 2, 2004 (May). |
|
| Click here to learn more (pdf) |
|
|
|
| Taxotere® Market Share Submission Reminder |
|
| According to the OA group contract terms, in order for an individual practice to receive a discount for all Taxotere® purchases, you must report your market share data to the Aventis Taxotere® Market Share website. This site will enable you to report your quarterly purchases, credits/returns for all products within the Taxotere® Therapeutic Category (Taxotere®, paclitaxel and gemcitabine). |
|
| Click here to learn more (pdf) |
|
|
|
| New Agent, Vidaza added to Pharmion |
|
| We are pleased to announce the launch of Vidaza (azacitidine for injectable suspension) and its addition to the Pharmion agreement. This product will become available to all OA Members in good standing July 1, 2004. Vidaza is available in 100 mg vials and is indicated for the treatment of all five Myelodysplastic Syndrome (MDS) subtypes. |
|
| Click here to learn more (pdf) |
|
|
|
| Exciting Enhancements to Roche |
|
| Oncology Associates is pleased to announce the following improvements to the Roche agreement for Kytril: |
|
| Start Date of July 1, 2004 |
|
| The minimum annual 5HT3 DDD dollars required for Super Tier pricing shall be significantly lowered from $1,000,000 to $500,000. |
|
| Kytril Market Share will be determined using DDD Dollars and is calculated as the sum of Kytril sales divided by the sum of all 5HT3 Market sales. |
|
| Click here to learn more (pdf) |
|
|
|
| Carboplatin Now Available Through SICOR |
|
| Effective June 24, 2004, the following products have been added to the SICOR Agreement for OA Members: |
|
|
Carboplatin Injection
Carboplatin for Injection
Liquid Fludarabine
|
|
| Click here to learn more (pdf) |
|
|
|
| New Sandostatin LAR® Agreement - Novartis |
|
| Oncology Associates is pleased to announce its agreement with Novartis for Sandostatin LAR®. The terms of the new agreement became effective April 1, 2004 and run through December 31, 2004. |
|
| Click here to learn more (pdf) |
|
|
|
| New Lower Taxotere Prices for OA Members! |
|
| Effective February 15, 2004 |
|
| Oncology Associates is pleased to announce a new agreement with Aventis. This agreement will enable OA Members to receive the maximum discounting structure available for Taxotere®. OA Members currently attached to the OA Taxotere® agreement with a signed declaration letter on file were automatically enrolled in the new contract February 15, 2004. |
|
| Click here to learn more (pdf) |
|
|
|
| New Amgen Agreement |
|
| Oncology Associates is pleased to announce a new and simplified Amgen Portfolio Contract (APC) for 2004. The contract term began March 1, 2004 and extends to 2006. Please contact your Amgen Sales Representative to find out how you can begin earning these quarterly rebates. For more information, contact OA at 888-732-7352. |
|
| Click here to learn more (pdf) |
|
|
|
| Roche Agreement Reminder for Kytril |
|
| Effective January 1, 2004 |
|
| Oncology Associates remind you of its new agreement with Roche for Kytril® (granisetron hydrochloride). This members' product contract includes 1mL single dose vials and 4 mL multi dose vials of Kytril®. |
|
| This exciting agreement offers a rebate as well as additional enhancements of a new super tier pricing level for those who qualify. The terms of the new contract became effective January 1, 2004. Contact your Roche Oncology Specialist to learn all of the details regarding this new agreement. |
|
|
|
| 4 New Products Added to SICOR Agreement |
|
| Effective November 6, 2003 |
|
| The following products have been added as part of the OA/SICOR agreement: |
|
IDArubicin Hydrochloride Injection
Indicated for the treatment of Leukemia and is offered in 5 mL, 10 mL, and 20 mL vials. |
|
Ifosfamide/Mesna Kit
Indicated for the treatment of testicular cancer and is offered in the following sizes: 5/3 g; 10/10 g; 2/6 g. |
|
Leuprolide Acetate
Indicated in the palliative treatment of advanced prostatic cancer, is offered in 2.8 mL vials. |
|
Mesna Injection
A detoxifying agent used to inhibit the hemorrhagic cystitis induced by ifosfamide and is offered in 10 mL vials. |
|
|
|
| Roche Offers New Contract for Kytril®! |
|
| Effective November 1, 2003 |
|
| Oncology Associates has signed a new contract with Roche for Kytril® (granisetron hydrochloride). This members' product contract includes 1mL single dose vials and 4 mL multi dose vials of Kytril®. New additions to the contract include a significant rebate as well as an additional super tier price level. |
|
|
|
| New Enhancements to the Amgen Contract |
|
| Effective September 12, 2003 |
|
| Oncology Associates is pleased to announce new enhancements to the Amgen Shared Commitment (ASC) contract as well as an opportunity for non-ASC practices to participate in exciting new offers. |
|
| In addition to your physician clinic off-invoice discounts, rebates schedule and the standard ASC contract at a 5% Aranesp rebate, Amgen is now offering an enhanced contractual product that provides for an additional 2% for Aranesp and also a 2% rebate on Neupogen and Neulasta. |
|
|
|
| OA Signs Agreement with MGI PHARMA, Inc. for Aloxi™ |
|
| Effective September 8, 2003 |
|
| Oncology Associates now presents the first member's contract for Aloxi™ (palonosetron hydrochloride) from MGI PHARMA, Inc. Aloxi™ is offered as an injection at a dose of 0.25 mg for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. Aloxi™ is also indicated for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. |
|
|
|
| FIS Now Stocks Innohep® for Treatment of DVT |
|
| Effective Immediately |
|
| Innohep® is now available through FloridaInfusion Services. Contact FIS directly at 800-624-0152 to place an order. Innohep® (tinzaparin sodium for injection) is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®). |
|
|
|
| Aranesp® SingleJect® Prefilled Syringes Now Available to OA Members |
|
| Effective July 28, 2003 |
|
| Oncology Associates is pleased to announce the addition of Aranesp® SingleJect® Prefilled Syringes to the Amgen contract. Single-use syringes are available in the following sizes: 60 mcg, 0.3 mL; 100 mcg, 0.5 mL; 200 mcg, 0.4 mL; and 300 mcg, 0.6 mcg. As an OA member on the Amgen contract, you automatically qualify for this new savings benefit. |
|
|
|
| OA Adds ADRUCIL® Injection and Fludarabine to SICOR Agreement ADRUCIL® Injection |
|
| Effective September 15, 2003 |
|
| ADRUCIL (fluorouracil injection, USP) is now offered as part of the OA/SICOR Agreement. ADRUCIL®, an antineoplastic antimetabolite, is a sterile, nonpyrogenic injectable solution for intravenous administration. Each 10 mL contains 500 mg fluorouracil; pH is adjusted to approximately 9.2 with sodium hydroxide. |
|
| Fludarabine Phosphate for Injection is available to OA members. Fludarabine Phosphate for Injection is offered in 50 mg/6 mL vials. Fludarabine Phosphate for Injection is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. |
|
|
|
| OA Signs Contract with Sicor for Vinorelbine Tartrate Injection |
|
| Effective June 17, 2003 |
|
| Vinorelbine Tartrate is a semi-synthetic vinca alkaloid with anti-tumor activity. Each vial contains 10 mg (1-mL vial) or 50 mg (5-mL vial) of Vinorelbine Tartrate in water for intravenous administration. |
|
|
|
| New Amendment for Amgen Multiproduct contract |
|
| Aranesp™, Neulasta™ and Neupogen® |
|
| Runs from June 1, 2003 to July 15, 2004 |
|
| Members will earn an improved rebate for all Amgen contracted product purchases made from June 1, 2003 to July 15, 2004. Members will have access to OA's group agreement off-invoice discounts for all contracted Amgen products as well as a possible supplemental rebate. Contact Oncology Associates with any questions regarding this contract at 888-732-7352. |
|
|
|
| GlaxoSmithKline offers new contract! |
|
| Effective July 1, 2003 |
|
| A new clinic contract offering from GlaxoSmithKline is now available to OA members. Products on contract include: Hycamtin, Navelbine and Zofran Injection 20ml vials and 32mg premixed bags. |
|
|
|
| New Bedford Labs contract for Paclitaxel® |
|
| Effective January 21, 2003 |
|
| Paclitaxel® is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. Paclitaxel® is also indicated for the treatment of breast cancer after failure of combination chemotherapy for metastic disease or relapse within six months of adjuvant chemotherapy. |
|
|
|
| Contract Renewal for Aventis' Taxotere® |
|
| Effective January 1, 2003 |
|
| Taxotere® (docetaxel) is an antineoplastic agent belonging to the taxoid family. It is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy and the treatment of patients with locally advanced or metastatic non-small lung cancer after failure of prior platinum-based chemotherapy. |
|
|
|
| New Pharmion contract for Innohep® |
|
| Effective December 1, 2002 |
|
| Innohep® (tinzaparin sodium for injection) is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®). |
|
|
|
| New MedImmune Oncology contract for Ethyol® |
|
| Effective October 17, 2002 |
|
| Ethyol® (amifostine) is a selective cytoprotective agent used to reduce toxicities associated with certain cancer chemotherapy and radiotherapy. |
|
